|
KMID : 0358419940370122443
|
|
Korean Journal of Obstetrics and Gynecology
1994 Volume.37 No. 12 p.2443 ~ p.2452
|
|
|
Human HER-2/neu(c-erbB-2) Oncoprotein in Sera and Tissue of Patients with Ovarian Cancer
|
|
김경태
김성진/유중배/조수현/조삼현/황윤영/문형/이재억/장성열
|
|
|
Abstract
|
|
|
The HER-2/neu(c-erbB-2) oncogene product p 185 neu is expressed by most ovarian cancers and overexpressed in approximately 30%. This overexpression is correlated with poor clinical outcome, as measured by time to relapse and overall survival
time.
In
the present study, the quantitative measurement of HER-2/neu protein and CA 125 antigen levels in sera were done in 34 patients with diagnosed epithelial ovarian cancer, 23 patients with cervical cancer, and 20 controls. The mean value of ovarian
cancer
patients(22.2±18.6 Units/ml) was higher compared with that ot cervical cancer(15.4±3.7 Units/ml), or control sera(14.0±4.3 Units/ml). Elevated levels(> 22.6 Units/ml) of circulating neu determinants have been detected in sera from 11(34%) of
34
patients.
Tissue levels of neu from the same patients were also determined by immunohistochemical staining with anti-neu polyclonal antibody. Of 34 patients who had paraffin embedded tissue block, overexpression(+++) of neu was found in 9 by
immunohistochemical
analysis : of these 9, serum neu levels were elevated in 6(67%). Among the 23 patients with normal to moderate tissue expression of neu, only 3(13%) had elevated serum neu levels. Thus, elevated serum neu levels predicted tissue overexpression
with
a
specificity of 87%(p=0.0173).
Serum and tissue levels of neu correlate in patients with epithelial ovarian cancer. However serum neu levels were not related to the levels of CA 125. Survival of the patients with high serum HER-2/neu was less likely to have worse than that of
the
patients with normal HER-2/neu level(Median survival : 21.45 vs 41.65 months). Therefore the quantitative measurement of the HER-2/neu oncorprotein in sera may have value in the overexpression of HER-2/neu oncoprotein of patients with diagnosed
ovarian
cancer. These findings suggest that HER-2/neu deserve further evaluation as a prognostic marker in patients with epithelial ovarian cancer.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|